Al Hammadi Company for Development and Investment terminated the memorandum of understanding (MoU) signed with Sudair Pharma Co. for a potential acquisition.
The termination came as no final agreement was reached on the deal conditions, Al Hammadi said in statement to Tadawul on Sunday.
Last April, the healthcare services provider inked a two-month MoU with Sudair Pharma Co. for a potential acquisition of equity stake in the latter, Argaam reported.
Al Hammadi the preliminary agreement until Aug. 31.
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}